STAT5 is essential for IL-7–mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells by Daniel Ribeiro, Alice Melão,

Slides:



Advertisements
Similar presentations
STAT3 mediates oncogenic addiction to TEL-AML1 in t(12;21) acute lymphoblastic leukemia by Maurizio Mangolini, Jasper de Boer, Vanessa Walf-Vorderwülbecke,
Advertisements

The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKCθ and ERK pathways by Gilles Despouy, Marjorie Joiner, Emilie Le Toriellec,
by Paritosh Ghosh, Meredith A
EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression
Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells by Duohui Jing, Vivek A.
by Christopher J. Ott, Nadja Kopp, Liat Bird, Ronald M
Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells by Aleksandar Petlickovski,
Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation by Shiguo Zhu, Prasad V. Phatarpekar,
CD300a is expressed on human B cells, modulates BCR-mediated signaling, and its expression is down-regulated in HIV infection by Rodolfo Silva, Susan Moir,
Cytokine-inducible CD40 expression in human endothelial cells is mediated by interferon regulatory factor-1 by Andreas H. Wagner, Matthias Gebauer, Beatrix.
Volume 16, Issue 12, Pages (September 2016)
by Takahiro Kamiya, Desmond Wong, Yi Tian Png, and Dario Campana
Functional human regulatory T cells fail to control autoimmune inflammation due to PKB/c-akt hyperactivation in effector cells by Ellen J. Wehrens, Gerdien.
by Juan M. Cárcamo, Oriana Bórquez-Ojeda, and David W. Golde
by Andrea Crotti, Marina Lusic, Rossella Lupo, Patricia M. J
Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia by Shannon L. Maude, Sibasish.
Volume 11, Issue 2, Pages (August 2012)
Volume 16, Issue 9, Pages (August 2016)
Volume 44, Issue 3, Pages (November 2011)
Volume 54, Issue 1, Pages (April 2014)
Gene expression and genomic profiling reveal estrogen-independent ER transcriptional activity. Gene expression and genomic profiling reveal estrogen-independent.
Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function by Alfonso Catalano, Paola Caprari, Simona Moretti, Monica.
Volume 44, Issue 3, Pages (November 2011)
Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival by Kyu-Tae Kim, Kristin Baird, Joon-Young Ahn, Paul.
Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia by Shahrzad Jalali, Tammy Price-Troska, Jonas Paludo, Jose Villasboas, Hyo-Jin.
by Kentson Lam, Alexander Muselman, Randal Du, Yuka Harada, Amanda G
Identification of TLOC1 and SKIL as tumor driver genes in 3q26.
by Reuben Kapur, Ryan Cooper, Lei Zhang, and David A. Williams
Volume 17, Issue 4, Pages (October 2015)
Akio Horiguchi, Mototsugu Oya, Ken Marumo, Masaru Murai 
MiR-34a contributes to megakaryocytic differentiation of K562 cells independently of p53 by Francisco Navarro, David Gutman, Eti Meire, Mario Cáceres,
Dynamic change of transcription pausing through modulating NELF protein stability regulates granulocytic differentiation by Xiuli Liu, Aishwarya A. Gogate,
Volume 16, Issue 12, Pages (September 2016)
Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma by Hanna Karvonen, David Chiron, Wilhelmiina Niininen,
Volume 18, Issue 5, Pages (January 2017)
by Silvia Mele, Stephen Devereux, Andrea G
RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs by Mylène Gerritsen, Guoqiang Yi,
Volume 16, Issue 6, Pages (June 2015)
C/EBPα overrides epigenetic reprogramming by oncogenic transcription factors in acute myeloid leukemia by Justin Loke, Paulynn Suyin Chin, Peter Keane,
Leslie van der Fits, Jacoba J. Out-Luiting, Cornelis P
by Nur-Taz Rahman, Vincent P. Schulz, Lin Wang, Patrick G
Naoko Kanda, Shinichi Watanabe  Journal of Investigative Dermatology 
Volume 44, Issue 3, Pages (November 2011)
Myeloma cell–derived Runx2 promotes myeloma progression in bone
Volume 9, Issue 5, Pages (November 2017)
The IL-6 Trans-Signaling-STAT3 Pathway Mediates ECM and Cellular Proliferation in Fibroblasts from Hypertrophic Scar  Sutapa Ray, Xiaoxi Ju, Hong Sun,
ADAR Regulates RNA Editing, Transcript Stability, and Gene Expression
Volume 10, Issue 3, Pages (September 2006)
Volume 35, Issue 2, Pages (August 2011)
Nonsense-Mediated RNA Decay Influences Human Embryonic Stem Cell Fate
Paradoxical enhancement of leukemogenesis in acute myeloid leukemia with moderately attenuated RUNX1 expressions by Ken Morita, Shintaro Maeda, Kensho.
Volume 23, Issue 3, Pages (April 2018)
Twist1 regulates embryonic hematopoietic differentiation through binding to Myb and Gata2 promoter regions by Kasem Kulkeaw, Tomoko Inoue, Tadafumi Iino,
C/EBPβ is a critical mediator of IFN-α–induced exhaustion of chronic myeloid leukemia stem cells by Asumi Yokota, Hideyo Hirai, Ryuichi Sato, Hiroko Adachi,
by Defne Bayik, Debra Tross, Lydia A
The oncogenic membrane protein LMP1 sequesters TRAF3 in B-cell lymphoma cells to produce functional TRAF3 deficiency by Pradeep Bangalore-Prakash, Laura.
Volume 39, Issue 3, Pages (September 2013)
Volume 70, Issue 5, Pages (September 2006)
by Rodrigo Abreu, Frederick Quinn, and Pramod K. Giri
Volume 33, Issue 1, Pages (July 2010)
Defective RAB1B-related megakaryocytic ER-to-Golgi transport in RUNX1 haplodeficiency: impact on von Willebrand factor by Gauthami Jalagadugula, Lawrence.
CD86 regulates myeloma cell survival
by Pamela J. Sung, Mayumi Sugita, Holly Koblish, Alexander E
IL-33, IL-25, and TSLP induce a distinct phenotypic and activation profile in human type 2 innate lymphoid cells by Ana Camelo, Guglielmo Rosignoli, Yoichiro.
Senescence-associated defective HLA-DR upregulation does not modulate immunosuppressive properties of MSCs. (A) Fit and senescent MSCs were subjected to.
The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.
Transcriptional and genomic targets of EN1 in TNBC cells.
Volume 19, Issue 5, Pages (May 2017)
HOXA9 and STAT5 co-occupy similar genomic regions and increase JAK/STAT signaling. HOXA9 and STAT5 co-occupy similar genomic regions and increase JAK/STAT.
Volume 18, Issue 5, Pages (January 2017)
Presentation transcript:

STAT5 is essential for IL-7–mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells by Daniel Ribeiro, Alice Melão, Ruben van Boxtel, Cristina I. Santos, Ana Silva, Milene C. Silva, Bruno A. Cardoso, Paul J. Coffer, and João T. Barata BloodAdv Volume 2(17):2199-2213 September 11, 2018 © 2018 by The American Society of Hematology

Daniel Ribeiro et al. Blood Adv 2018;2:2199-2213 © 2018 by The American Society of Hematology

Akt activation fully mimics IL-7-induced T-ALL cell growth and cell cycle progression but does not completely recapitulate the effects on cell viability. Akt activation fully mimics IL-7-induced T-ALL cell growth and cell cycle progression but does not completely recapitulate the effects on cell viability. HPB-ALL cells were stably transduced with retroviral vectors driving the expression of constitutively active, myristoylated-Akt (myrAkt), or empty control (Empty). (A) Transduced, regularly cultured HPB-ALL cells collected for immunoblot analysis of Akt expression (Akt) and PI3K/Akt, JAK/STAT5, and MEK/extracellular signal-regulated kinase (ERK) pathway activation (P-Akt, P-STAT5, and P-ERK1/2, respectively). Starved transduced HPB-ALL cells were stimulated or not with IL-7 (20 ng/mL) and were assessed by flow cytometry analysis of cell growth at 96 hours (B), cell cycle at 72 hours (C) and viability at 96 hours (D). Daniel Ribeiro et al. Blood Adv 2018;2:2199-2213 © 2018 by The American Society of Hematology

JAK/STAT5 pathway activation is required for IL-7-induced T-ALL cell viability and growth. JAK/STAT5 pathway activation is required for IL-7-induced T-ALL cell viability and growth. (A) IL-7-starved TAIL7 cells were incubated with IL-7 for the indicated periods of time, and JAK-STAT5 pathway activation was analyzed by immunoblot. In the P-JAK1/3 panel, the upper bands correspond to P-JAK1 and the lower bands to P-JAK3. Results are representative of at least 2 independent experiments. (B) TAIL7 cells were nucleofected with pGL3-β-casein-firefly luciferase vector and pGL4-SV40-Renilla luciferase, followed by IL-7 stimulation for 24 hours. Luciferase activity from cell extracts was measured in a luminometer. STAT5 transcriptional activity was calculated as described in “Methods.” (C) Primary T-ALL or PDX cells were stimulated with IL-7 for 15 minutes or 2 hours, respectively, followed by immunoblot analysis of STAT5 activation. Data representative of 2 patients and 3 PDX analyzed. (D) HPB-ALL cells, stably transduced with STAT5A shRNA (shSTAT5) or scramble control (shSCR), were stimulated with IL-7 for 15 minutes and evaluated for STAT5 activation (P-STAT5) and total STAT5 expression. (E) Stably transduced HPB-ALL cells cultured for 72 hours in the indicated conditions were assessed for viability and cell growth. Results are representative of 3 independent experiments. Graphics represent average of triplicates ± standard error of the mean (SEM). Daniel Ribeiro et al. Blood Adv 2018;2:2199-2213 © 2018 by The American Society of Hematology

STAT5 inhibition abrogates IL-7–mediated T-ALL cell viability, cell growth, cell cycle progression, and proliferation. STAT5 inhibition abrogates IL-7–mediated T-ALL cell viability, cell growth, cell cycle progression, and proliferation. IL-7-deprived TAIL7 or primary T-ALL cells were cultured in medium, IL-7, or IL-7 plus S5i (100 µM and 150 µM, respectively). Cell viability (A-B), cell growth (C-D), cell cycle (E), and proliferation (F) were determined at 72 hours. Results are representative of at least 2 independent experiments or patients. Graphics represent average of triplicates ± SEM. **P < .01; ***P < .001. Daniel Ribeiro et al. Blood Adv 2018;2:2199-2213 © 2018 by The American Society of Hematology

STAT5 inhibition abrogates IL-7–mediated upregulation of CD71, and downregulation of p27kip1, but not upregulation of Bcl-2 in T-ALL cells. STAT5 inhibition abrogates IL-7–mediated upregulation of CD71, and downregulation of p27kip1, but not upregulation of Bcl-2 in T-ALL cells. IL-7-deprived TAIL7 or primary T-ALL cells were cultured for 72 hours in medium, IL-7, or IL-7 plus S5i, and analyzed for CD71 surface expression (A-B), expression of p27kip1 (C), and Bcl-2 levels (D-E). Mean fluorescence intensity (MFI) values are indicated for each flow cytometry histogram. Vertical lines indicate peak value in medium alone. (F) Under the same experimental conditions, TAIL7 cells were collected at 24 hours, and BCL2 transcript levels determined by qPCR. Fold induction is normalized to the medium alone. Results are representative of at least 2 independent experiments or 3 patients. Graphics represent average of triplicates ± SEM. **P < .01; ***P < .001. ns, not significant (P ≥ .05). Daniel Ribeiro et al. Blood Adv 2018;2:2199-2213 © 2018 by The American Society of Hematology

Cross-analysis of STAT5 ChIP-seq and RNA-seq data on IL-7-stimulated TAIL7 cells. Cross-analysis of STAT5 ChIP-seq and RNA-seq data on IL-7-stimulated TAIL7 cells. IL-7-deprived TAIL7 cells were cultured with or without IL-7 for 24 hours, and then collected for STAT5 ChIP-seq or RNA-seq enriched for mRNA. (A) Relative STAT5 peak enrichment/depletion in IL-7-stimulated cells. The relative enrichment of each STAT5 peak interval was calculated as described in “Methods.” Value of 0 equals random binding, negative values indicate STAT5 depletion, and positive values indicate STAT5 enrichment. (B) De novo motif discovery and identification on STAT5 ChiP-seq peaks from IL-7-stimulated cells. Enrichment cutoff at 1.5. The “Presence” column denotes the relative presence of the motif on all peaks. “Average motif/peak” denotes the number of times a motif appears on the peak. (C) Graph showing the distance, in base pairs (bp), of RUNX motifs to the STAT motif (horizontal axis) within each peak found in panel B, plotted against the frequency of each occurrence (vertical axis). (D) Venn diagram showing the overlap of genes found in the RNA-seq analysis (purple and yellow sets) and ChIP-seq analysis (green and red sets). Analysis was performed with genes with a STAT5a peak within 20 kb from the transcription start site. The genes with an IL-7-induced STAT5 peak whose expression was up- or downregulated by IL-7 are indicated on the left and right lists, respectively. (E) qPCR validation of ChIP-seq and RNA-seq data. IL-7-deprived TAIL7 cells cultured in medium, IL-7, or IL-7 plus S5i were collected for mRNA extraction and qPCR analysis at 24 hours (HRH2, CISH, OSM, and PIM1) or 48 hours (BCL6 and IL10). Fold change is normalized for the medium condition. Validation results are representative of at least 3 independent experiments. Results represent average of triplicates ± SEM. Daniel Ribeiro et al. Blood Adv 2018;2:2199-2213 © 2018 by The American Society of Hematology

IL-7 directly modulates PIM1 and BCL6 expression via STAT5. IL-7 directly modulates PIM1 and BCL6 expression via STAT5. (A) TAIL7 cells were withdrawn or not from IL-7 for 96 hours and collected for immunoblot analysis of BCL6, P-STAT5, and STAT5. (B) Data from ChIP-seq and RNA-seq were uploaded to University of California, Santa Cruz genome browser visualization tool (top 6 tracks). The browser is centered on the human BCL6 gene locus (hg19). Custom tracks are paired as control (Medium) and IL-7. ChIP STAT5 track pair represents peaks found upon STAT5 IP, and the arrow highlights a STAT5 binding peak. Input track represents control input for ChIP. RNA-seq track represents mRNA expression. Peak height is proportional to the expression. The bottom arrow in RNA-seq tracks highlights the decrease in overall BCL6 gene expression and concomitant processing of intron 1 into the mRNA. (C) IL-7-deprived TAIL7 cells were cultured for 72 hours in medium, IL-7, or IL-7 plus S5i and analyzed for P-STAT5 and PIM1. (D) Serum-starved, stably transduced HPB-ALL cells were cultured with or without IL-7 for 24 hours and analyzed for P-STAT5, PIM1, and P-Akt. Results are representative of at least 3 independent experiments. Daniel Ribeiro et al. Blood Adv 2018;2:2199-2213 © 2018 by The American Society of Hematology

PIM inhibition abrogates IL-7–mediated T-ALL cell growth, proliferation, cell cycle progression, and CD71 expression but does not impact cell viability or Bcl-2 expression. PIM inhibition abrogates IL-7–mediated T-ALL cell growth, proliferation, cell cycle progression, and CD71 expression but does not impact cell viability or Bcl-2 expression. IL-7-deprived TAIL7 or PDX T-ALL cells were cultured in medium, IL-7, or IL-7 plus the pan-PIM inhibitor AZD1208 (1 µM) and analyzed by flow cytometry for viability (A), intracellular Bcl-2 levels (B), cell size (C), CD71 surface expression (E), cell cycle (D), and proliferation (F). Results are representative of 2 independent experiments or 2 PDX. Results in graphics represent average of triplicates ± SEM. *P < .05; **P < .01; ***P < .001. Daniel Ribeiro et al. Blood Adv 2018;2:2199-2213 © 2018 by The American Society of Hematology